OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
31 mrt 2011 - 09:05
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus' licensee Biolex presents Phase IIb results at EASL showing reduced rates of depression in HCV patients treated with Locteron
Bericht
Locteron’s next-generation controlled-release mechanism is designed to provide key tolerability and dosing advantages over currently marketed interferons
Locteron may address one of the most significant side effects associated with the use of current interferon products in the treatment of HCV
Leiden, the Netherlands, 31 March 2011 - OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces that its licensee Biolex Therapeutics will present today final results from the Locteron® Phase IIb clinical study at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany. These data show substantially reduced rates of depression in patients treated with Locteron, compared to current HCV treatments.
Jan Egberts, CEO of OctoPlus, comments: “These positive final results from the Phase IIb clinical study with Locteron further confirm the long term benefits of Locteron’s controlled release mechanism and even show a significant advantage in depression related side effects. Our PolyActive technology has enabled the development of an interferon alpha with a significantly improved side effect profile, achieving both a 50% reduction in flu-like adverse events and substantially lower rates of depression, compared to conventional interferon treatments. In combination with its reduced injection frequency, these benefits clearly position Locteron as the interferon of choice for future hepatitis C treatments.”
Datum laatste update: 08 oktober 2024